zeteletinib   Click here for help

GtoPdb Ligand ID: 11416

Synonyms: BOS-172738 | BOS172738 | DS-5010 | DS5010 | Example 3 [WO2018060714A1]
Compound class: Synthetic organic
Comment: This entry was generated from the chemical structure for the INN zeteletinib, which resolved via PubChem and SureChEMBL to Daiichi Sankyo patent WO2018060714A1 [1]. The compounds in this patent are claimed as RET kinase inhibitors, principally for the treatment of proliferative diseases. The zeteletinib structure is claimed as Example 3. In the absence of formal name>structure disclosure we have been unable to determine the clinical development stage of this compound.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 99.37
Molecular weight 500.17
XLogP 4.39
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc2cc(cnc2cc1OC)c1ccc(cn1)CC(=O)Nc1onc(c1)C(C(F)(F)F)(C)C
Isomeric SMILES COc1cc2cc(cnc2cc1OC)c1ccc(cn1)CC(=O)Nc1onc(c1)C(C(F)(F)F)(C)C
InChI InChI=1S/C25H23F3N4O4/c1-24(2,25(26,27)28)21-11-23(36-32-21)31-22(33)7-14-5-6-17(29-12-14)16-8-15-9-19(34-3)20(35-4)10-18(15)30-13-16/h5-6,8-13H,7H2,1-4H3,(H,31,33)
InChI Key KOLQINCWMXQEOF-UHFFFAOYSA-N
Bioactivity Comments
Potently inhibits wild type RET and RETV804L in biochemical and cell-based assays [1].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
ret proto-oncogene Hs Inhibitor Inhibition 8.3 pIC50 - 1
pIC50 8.3 (IC50 4.6x10-9 M) [1]